据Sai生命科学组织报告,在CDMO增长和大量新投资的推动下,收入猛增了77%。 Sai Life Sciences reports 77% revenue jump, driven by CDMO growth and significant new investments.

Sai Life Science公司是一家合同研究和制造公司,其收入逐年猛增77%,在2026年财政年度第一季度增至496库罗尔。 Sai Life Sciences, a contract research and manufacturing company, saw its revenue surge 77% year-over-year to ₹496 crores in the first quarter of fiscal 2026. 强劲增长主要是由于CDMO部分的强劲扩展,EBITDA公司增加了305%,达到125克朗。 The strong growth was mainly due to a robust expansion in its CDMO segment, with EBITDA increasing 305% to ₹125 crores. 该公司还在新设施中投资134卢比,以支持先进的药物开发,包括peptides和抗体药物共产物。 The company also invested ₹134 crores in new facilities to support advanced drug development, including peptides and antibody-drug conjugates.